Your browser is no longer supported. Please, upgrade your browser.
Settings
EYEG EyeGate Pharmaceuticals, Inc. daily Stock Chart
EYEG [NASD]
EyeGate Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.67 Insider Own3.10% Shs Outstand4.54M Perf Week2.11%
Market Cap18.90M Forward P/E- EPS next Y-1.59 Insider Trans0.00% Shs Float4.44M Perf Month-5.37%
Income-9.80M PEG- EPS next Q-0.42 Inst Own42.20% Short Float0.75% Perf Quarter-23.17%
Sales0.00M P/S- EPS this Y51.20% Inst Trans-0.10% Short Ratio0.16 Perf Half Y-13.59%
Book/sh1.72 P/B2.26 EPS next Y18.50% ROA-93.00% Target Price- Perf Year21.25%
Cash/sh0.97 P/C4.02 EPS next 5Y- ROE-135.40% 52W Range2.75 - 12.89 Perf YTD-61.28%
Dividend- P/FCF- EPS past 5Y11.50% ROI-109.20% 52W High-69.90% Beta1.17
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low41.09% ATR0.23
Employees10 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)48.03 Volatility4.82% 5.56%
OptionableNo Debt/Eq0.00 EPS Q/Q39.90% Profit Margin- Rel Volume0.10 Prev Close3.65
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume204.45K Price3.88
Recom2.00 SMA200.88% SMA50-9.57% SMA200-28.53% Volume21,408 Change6.30%
Feb-06-18Reiterated H.C. Wainwright Buy $5 → $3
Apr-07-16Initiated Noble Financial Buy $10
Feb-01-16Initiated Rodman & Renshaw Buy $10
Dec-23-15Initiated Chardan Capital Markets Buy $6
Nov-12-15Initiated Maxim Group Buy $11
Sep-25-20 10:48AM  
Sep-08-20 06:55AM  
Aug-12-20 06:55AM  
Aug-06-20 04:15PM  
Jul-14-20 06:55AM  
Jun-11-20 06:55AM  
Jun-01-20 06:55AM  
May-19-20 09:11AM  
May-06-20 04:15PM  
09:10AM  
Apr-01-20 09:04AM  
Mar-31-20 06:55AM  
Mar-04-20 04:15PM  
Jan-06-20 06:55AM  
Jan-03-20 10:25AM  
Dec-31-19 09:25AM  
Dec-17-19 06:55AM  
Dec-02-19 06:55AM  
Nov-22-19 09:02AM  
08:37AM  
06:55AM  
Nov-14-19 10:15AM  
Nov-07-19 06:55AM  
Oct-09-19 06:55AM  
06:55AM  
Sep-30-19 06:55AM  
Sep-23-19 06:55AM  
Sep-16-19 06:55AM  
Sep-03-19 06:55AM  
Aug-29-19 12:45PM  
Aug-26-19 06:55AM  
Aug-08-19 06:55AM  
Aug-05-19 12:21PM  
09:00AM  
06:55AM  
Jul-31-19 06:55AM  
Jul-09-19 06:55AM  
Jun-26-19 06:55AM  
Jun-05-19 10:00AM  
Jun-03-19 06:55AM  
May-14-19 06:55AM  
May-08-19 04:15PM  
May-02-19 02:00PM  
06:55AM  
Mar-28-19 10:00AM  
Mar-26-19 06:55AM  
Mar-01-19 04:05PM  
Jan-29-19 06:55AM  
Jan-16-19 06:55AM  
Nov-30-18 12:30PM  
Nov-21-18 08:45AM  
Nov-14-18 11:20AM  
06:50AM  
Nov-13-18 04:05PM  
09:50AM  
06:55AM  
06:55AM  
Oct-02-18 06:55AM  
Sep-28-18 11:45AM  
Sep-25-18 06:55AM  
Sep-24-18 06:55AM  
Sep-04-18 08:31AM  
08:30AM  
Aug-29-18 08:30AM  
Aug-20-18 08:30AM  
Aug-07-18 08:30AM  
Aug-03-18 08:30AM  
Jul-26-18 09:30AM  
09:20AM  
Jul-24-18 08:30AM  
Jul-10-18 07:45AM  
Jun-22-18 08:30AM  
Jun-11-18 07:00AM  
May-30-18 08:30AM  
May-29-18 10:35AM  
May-25-18 09:37PM  
May-22-18 08:30AM  
May-16-18 04:30PM  
May-11-18 08:30AM  
May-07-18 08:11AM  
Apr-17-18 04:30PM  
Apr-13-18 07:00AM  
Apr-11-18 08:30AM  
Apr-09-18 08:30AM  
Apr-06-18 08:30AM  
Mar-09-18 08:30AM  
Mar-08-18 03:31PM  
08:30AM  
Mar-02-18 04:28PM  
Feb-21-18 11:30AM  
Feb-07-18 08:30AM  
Feb-05-18 10:20AM  
08:30AM  
Jan-19-18 06:55PM  
Jan-04-18 08:30AM  
Jan-02-18 03:19PM  
Dec-25-17 11:54AM  
Dec-19-17 08:30AM  
Dec-18-17 08:30AM  
Dec-12-17 01:10PM  
EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye in the United States. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system. The company's CMHA-S based product, the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial wounds, defects, and epitheliopathies, as well as for re-epithelization of the ocular surface. It is also developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and anterior uveitis; and Eyegate II drug delivery system. The company has license agreements with the University of Miami School of Medicine; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.